US FDA approves Biocon unit's biosimilar to blockbuster eye drug Eylea-March 2024-www.financetom.com

US FDA approves Biocon unit's biosimilar to blockbuster eye drug Eylea

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves Biocon unit's biosimilar to blockbuster eye drug Eylea

May 20, 2024 8:00 AM

May 20 (Reuters) - The U.S. Food and Drug Administration

on Monday approved Biocon unit's biosimilar to

Regeneron Pharmaceuticals' ( REGN ) blockbuster eye drug Eylea,

according to information on the agency's website.

Previous page： Government aims to fetch Rs 5,316 crore through part-sale of Axis Bank stake Next page： Lower finance cost boosts Hindalco Industries and Utkal Q3 net 47% to Rs 713 crore

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Government aims to fetch Rs 5,316 crore through part-sale of Axis Bank stake

Feb 11, 2019

The offer for sale of up to 3 percent would be for two days from February 12 and is part of the government's disinvestment programme through which it aims to raise Rs 80,000 crore in the current fiscal.

Lower finance cost boosts Hindalco Industries and Utkal Q3 net 47% to Rs 713 crore

Feb 12, 2019

Hindalco Industries on Tuesday reported a 47.3 percent year-on-year (YoY) jump in net profit at Rs 713 crore for the December 2018 quarter.

Oil likely to be in $50-65 per barrel range, says BP CEO Bob Dudley

Feb 12, 2019

Gas major BP has announced $1 billion natural gas expansion in Egypt. In a conversation with CNBC's Dan Murphy, Bob...

Farm worker wage rises by 48% in nearly two-decades, says report

Feb 12, 2019

According to a report published by the ILO India Wage Report, the average daily wages of agricultural labourers was Rs 120 in 1993-94, while it became Rs 177 in 2011-12.